Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 206

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial

Open access
Supady, Alexander, Weber, Enya, Rieder, Marina, Lother, Achim, Niklaus, Tim, Zahn, Timm, Frech, Franziska, Müller, Sissi, Kuhl, Moritz, Benk, Christoph, Maier, Sven, Trummer, Georg, Flügler, Annabelle, Krüger, Kirsten, Sekandarzad, Asieb, Stachon, Peter, Zotzmann, Viviane, Bode, Christoph, Biever, Paul M, Staudacher, Dawid, Wengenmayer, Tobias, Graf, Erika, Duerschmied, Daniel·2021·The Lancet Respiratory Medicine

Abstract

Background We sought to clarify the benefit of cytokine adsorption in patients with COVID-19 supported with venovenous extracorporeal membrane oxygenation (ECMO). Methods We did a single-centre, open-label, randomised, controlled trial to investigate cytokine adsorption in adult patients with severe COVID-19 pneumonia requiring ECMO. Patients with COVID-19 selected for ECMO at the Freiburg University Medical Center (Freiburg, Germany) were randomly assigned (1:1) to receive cytokine adsorption using the CytoSorb device or not. Randomisation was computer-generated, allocation was concealed by opaque, sequentially numbered sealed envelopes. The CytoSorb device was incorporated into the ECMO circuit before connection to the patient circuit, replaced every 24 h, and removed after 72 h. The primary endpoint was serum interleukin-6 (IL-6) concentration 72 h after initiation of ECMO analysed by intention to treat. Secondary endpoints included 30-day survival. The trial is registered with ClinicalTrials.gov (NCT04324528) and the German Clinical Trials Register (DRKS00021300) and is closed. Findings From March 29, 2020, to Dec 29, 2020, of 34 patients assessed for eligibility, 17 (50%) were treated with cytokine adsorption and 17 (50%) without. Median IL-6 decreased from 357·0 pg/mL to 98·6 pg/mL in patients randomly assigned to cytokine adsorption and from 289·0 pg/mL to 112·0 pg/mL in the control group after 72 h. One patient in each group died before 72 h. Adjusted mean log IL-6 concentrations after 72 h were 0·30 higher in the cytokine adsorption group (95% CI −0·70 to 1·30, p=0·54). Survival after 30 days was three (18%) of 17 with cytokine adsorption and 13 (76%) of 17 without cytokine adsorption (p=0·0016). Interpretation Early initiation of cytokine adsorption in patients with severe COVID-19 and venovenous ECMO did not reduce serum IL-6 and had a negative effect on survival. Cytokine adsorption should not be used during the first days of ECMO support in COVID-19. Funding None.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(21)00177-6

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 206

Metadata

Authors
Supady, A., Weber, E., Rieder, M., Lother, A., Niklaus, T., Zahn, T., Frech, F., Müller, S., Kuhl, M., Benk, C., Maier, S., Trummer, G., Flügler, A., Krüger, K., Sekandarzad, A., Stachon, P., Zotzmann, V., Bode, C., Biever, P. M., Staudacher, D., Wengenmayer, T., Graf, E., & Duerschmied, D.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2021-07
Volume
9
Issue
7
Pages
755-762
ISSN
2213-2600 (ISSN-L)
OpenAlex
W3163397984
Cited by
206
References
5
FWCI
12.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. https://app.cochat.ai/papers/10.1016/s2213-2600(21)00177-6
The paper
Supady, A., Weber, E., Rieder, M., Lother, A., Niklaus, T., Zahn, T., Frech, F., Müller, S., Kuhl, M., Benk, C., Maier, S., Trummer, G., Flügler, A., Krüger, K., Sekandarzad, A., Stachon, P., Zotzmann, V., Bode, C., Biever, P. M., . . . Duerschmied, D. (2021). Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(21)00177-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.